Frederick R. Appelbaum

Oncology
825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 233 publications

Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.

Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.

Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025

Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML.

Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML.

Journal: Blood neoplasia
Published: November 21, 2025

Graft-versus-leukemia.

Graft-versus-leukemia.

Journal: Haematologica
Published: June 01, 2025

Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

Journal: JCO oncology practice
Published: March 20, 2025

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy.

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy.

Journal: Blood neoplasia
Published: February 24, 2025

Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia.

Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia.

Journal: Blood
Published: November 04, 2024

Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203.

Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203.

Journal: Leukemia
Published: October 01, 2024

Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia.

Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia.

Journal: Leukemia
Published: September 20, 2024

Second chances for secondary AML.

Second chances for secondary AML.

Journal: Blood advances
Published: August 13, 2024

Soiled soil.

Soiled soil.

Journal: Blood advances
Published: July 23, 2024

Offering patients a second chance: what is the minimum cure rate needed to justify allogeneic hematopoietic cell transplantation?

Offering patients a second chance: what is the minimum cure rate needed to justify allogeneic hematopoietic cell transplantation?

Journal: Leukemia
Published: June 25, 2024

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.

Journal: Blood
Published: May 15, 2024
Showing 1-12 of 233

Last Updated: 09/26/2026